Skip to content
Subscriber Only

Gene-Therapy Firm UniQure Explores Options Including Sale

From Gene-Editing Cures to Bioweapon Nightmare: Mark Buchanan

Photographer: Dhiraj Singh/Bloomberg

Updated on

UniQure NV is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy, people with knowledge of the matter said. The shares jumped.

The biotechnology company is working with advisers as it weighs options including a sale or partnerships, according to the people, who asked not to be identified because the information is private. UniQure’s shares have risen more than 151% in New York this year, giving it a market value of about $2.7 billion.